BioNTech Has More Cancer Drugs in Late-Stage Trials Than Most Investors Realize. Is It a Buy Under $100?

BioNTech's cancer pipeline is larger than its COVID-era reputation suggests, with several late-stage trials underway, making it an attractive investment under $100.